InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (2 ops.)
Insider track record
Board DirectorDisclosed buys
0
Disclosed sells
2
T+90 hit rate
0%
T+90 mean return
-25.7%
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the full record of transactions filed by Fischer Seth H. Z., Director. Director active across 6 companies, notably Agile Therapeutics INC. In total, 20 disclosures have been recorded. Split: 0 buy · 2 sells. Total volume traded: €10k. History available since 8 June 2021. The latest transaction was filed on 28 May 2026 (Attribution). Regulator: SEC (Form 4). All data is free.
Declarations20 total
79,873 shares0Common StockSEC:0001628280-26-039523:0
12,707 shares@ US$0.5552.2% of flowCommon StockSEC:0001104659-25-011247:0
976 shares@ US$1.52100.0% of flowCommon StockSEC:0001104659-24-092936:0
2,300 shares0Common StockSEC:0001415889-24-017635:0
23,000 shares0Common StockSEC:0001628280-24-025221:0
4,600 shares0Common StockSEC:0001415889-24-001598:0
54,066 sharesCommon Stock, $0.001 par valueSEC:0000899243-23-017672:0
5,150 shares0Common StockSEC:0001628280-23-022458:0
935 shares0Common StockSEC:0000929638-23-001712:0
1,018 shares@ US$6.5447.8% of flowCommon StockSEC:0001415889-23-002163:0
3,600 shares0Common StockSEC:0001415889-23-001556:0
25,000 shares0Common Stock, $0.001 par valueSEC:0001209191-22-048515:0
5,711 shares@ US$0.785100.0% of flowCommon Stock, $0.001 par valueSEC:0001209191-22-038810:0
670 shares0Common StockSEC:0001104659-22-070181:0
2,750 shares0Common StockSEC:0001104659-22-012784:0
2,750 shares0Common StockSEC:0001104659-22-012784
14,277 shares0Common Stock, $0.001 par valueSEC:0001209191-21-042453
14,277 shares0Common Stock, $0.001 par valueSEC:0001209191-21-042453:0
24,510 shares0Common StockSEC:0001104659-21-079621:0
24,510 shares0Common StockSEC:0001104659-21-079621
20 of 20 declarations
About Fischer Seth H. Z.
Seth H. Z. Fischer is a Director at AGILE THERAPEUTICS INC, SPECTRUM PHARMACEUTICALS INC, and MARINUS PHARMACEUTICALS INC. In this role, he contributes to the governance and strategy of these companies. His expertise in the biopharmaceutical sector is valuable in guiding research and development initiatives. As a director, he ensures that best practices are followed and that shareholder interests are protected.
